Top Emerging Cardio Vascular Device Companies - 2021
Second Heart Assist : Transcending The Barriers Of Circulatory

Top 10 Emerging Cardio Vascular Device Companies - 2021

Cardiovascular diseases are considered one of the leading pinpoints of the medical industry accounting for nearly one-third of all deaths across the world. Development and deployment of cardiovascular devices is a key part of the effort to mitigate cardiovascular diseases. Minimally invasive surgical procedures in the cardiovascular discipline offer a myriad of benefits like minimal damage to the body, less pain, and lower risk of complications as compared to open surgeries. Novel innovations like smart balloon catheter systems are equipped with electronics, sensors, and mechanisms.

Cardiac ablation devices account for almost 72 percent of the cardiovascular devices market share and is expected to gain massive momentum. The rising prevalence of atrial fibrillation is a major contributor to the popularity of such devices. These devices are addressing an ever-increasing demand for minimally invasive ablation procedures and innovation in cardiac ablation technologies. A large number of healthcare systems are integrating wearables into their remote patient monitoring programs to detect abnormally high heart rates, arrhythmias, and other factors. With the success of transcatheter aortic valve replacement, cardiologists attention has rapidly shifted toward transcatheter mitral valve repair and transcatheter tricuspid valve repair. This technology proves to be more beneficial than surgical valve replacements and can be performed as a same-day out-patient procedure.

At this juncture, there are a wide variety of solution providers entering the industry with a set of advanced cardiovascular devices. To help companies navigate through the best-of-breed cardiovascular device companies, MedTech Outlook has compiled a list of Top 10 as well as Emerging Cardiovascular Companies in 2021. The enlisted organizations offer innovative cardiovascular devices used to diagnose and treat heart diseases and related health problems. Besides, the magazine also comprises insights from thought leaders in the sector on the industry trends, best practices, recent innovations, and their advice for the aspiring CIOs.

We present to you MedTech Outlook’s, “Top 10 Emerging Cardiovascular Device Providers - 2021”

    Top Emerging Cardio Vascular Device Companies

    Anteris
    Anteris is a structural heart company focused on developing health solutions through better science and design. The company focuses on tissue science, valve design, and delivery system in the TAVR space providing products that last longer and works better in treating aortic stenosis. Anteris’ medical devices rely heavily on its proprietary ADAPT® tissue technology–an FDA-approved anti-calcification treatment platform technology and has been used in surgical repair for over 20,000 patients globally. Leveraging the remarkable technology, Anteris has built a novel and unique product, DurAVR™–the first and only 3D single-piece aortic valve. One of the key advantages of DurAVR™ is that they can restore normal pre-disease hemodynamics, making it far more anatomically correct than any other device currently available in the market
    Aquedeon Medical
    Aquedeon Medical was founded with the mission of reducing circulatory arrest time during open cardiothoracic surgery.The company’s Duett Vascular Graft System is designed as a modular solution to rapidly connect a patient’s native vessel to a synthetic one. It enables suture-less anastomoses - the system consists of a specialized Delivery System and a preloaded self-expanding Duett Vascular Graft. The Delivery System has a dual action slider. The first activation of the slider deploys the Duett Vascular Graft within the patient’s native vessel.The second deployment of the slider completes the anastomosis to the required graft
    Aria CV
    Aria offers a novel implantable device to improve the lives of patients suffering from the disease of pulmonary arterial hypertension. The company was co-founded by Dr. John Scandurra and Dr. Karl Vollmers, who at the time were Fellows at the University of Minnesota. The duo studied the medical literature and developed a novel approach to treating the disease. They developed early protoypes, tested them in animals, and filed a patent application for the device. The device is completely passive, i.e., it has no battery or electronics and is easy to use, which are vital factors when it comes to medical implants
    EBR Systems
    Delivers superior treatment for patients suffering from cardiac rhythm diseases by developing safe, clinically superior, cost-effective and reliable therapies using wireless cardiac stimulation. The company is on a mission to eliminate pacing leads and deliver top-of-the-line, reliable, and patient-specific treatment for cardiac rhythm diseases that would significantly help patients unable to benefit from the traditional CRT. EBR Systems’ WiSE CRT system is a leadless, customizable, and endocardial (inside the LV) therapy
    Second Heart Assist
    Offers an innovative circulatory assist platform to alleviate cardiovascular conditions
    Vesteck, Inc
    Established in 2019, Vesteck, Inc.provides an innovative cardiovascular device, VESTECK catheter that sutures endovascular aortic repair grafts to the aorta, eliminating migration, endoleaks that lead to complex, expensive repairs. The VESTECK endovascular suture delivery catheter comes sterile and preloaded with four Nitinol sutures. During an endovascular aortic aneurysm repair, once the interventionalistimplants the EVAR graft, they can use the VESTECK catheter to suture the graft to the aorta in a manner that it doesn’t move, slip or migrate.In contrast to other catheter-based technologies, the VESTECK catheter is much faster, safer, and simpler for physicians and patients alike. Key opinion leaders in the endovascular space acknowledge it as a leapfrog technology
    CardioDriven
    CardioDriven is an innovative medical device company focused on non-invasive diagnostic and treatment options within the field of cardiovascular medicine. We aim to provide world-class products to allow clinicians to take the best possible care of patients. Our mission is to identify clinical challenges and provide easy-to-use devices for patients and healthcare providers. We strive to innovate in the field of cardiovascular medicine with the goal of preserving life and improving quality of life
    Imricor
    Imricor was co-founded by Steve Wedan in 2006 and along with three Imricor pioneers established in the Twin Cities area. Imricor has quickly grown to be the first and only company in the world to bring commercially viable and safe iCMR products to the catheter ablation market. As Imricor continues to grow and develop this market, its focus is and remains the improvement of ablation therapy for patients all around the world
    Rheovector
    Rheovector is a development-stage company focused on delivering new diagnostics for earlier and more accurate prediction of acute cardiovascular events. Our purpose is simple: to reduce cardiovascular mortality and the overall cost of healthcare. Through basic science and clinical research, we are validating a pipeline of proprietary technologies that incorporate the most advanced in vitro diagnostics and vascular imaging tools. We are working to deliver new fluid dynamic markers that more accurately predict the progression of atherosclerosis and provide stronger, earlier signals for atherothrombosis
    Ventrix
    Ventrix is a clinical-stage company focused on the development of tissue engineering products for cardiovascular disease. Ventrix was founded based on a new approach to tissue engineering, focusing on repairing the microenvironment. We have guided our first product, VentriGel, from concept to the clinic. We have focused on the science behind VentriGel and are passionate about improving the quality of life of cardiovascular disease patients

Cardiovascular Devices Info

Q1
What Do Cardiovascular Device Companies Do?
Cardiovascular device companies develop technologies used to diagnose, monitor and treat heart and vascular conditions. Their work can include implantable devices, rhythm management systems, vascular access tools, cardiac monitoring devices, structural heart technologies and procedure-support equipment. In a Top Cardiovascular Device Companies listing, the focus is not only on product novelty but also on clinical relevance, reliability, physician usability and patient safety. Hospitals and specialty practices often look for companies that understand both device performance and the realities of cardiac care delivery.
Q2
Why Do Top Cardiovascular Device Companies Matter Now?
Top cardiovascular device companies are becoming increasingly important as healthcare systems face growing pressure from aging populations, rising rates of chronic heart disease and demand for less invasive treatment options. Hospitals and care teams are looking for technologies that help detect problems earlier, reduce procedure time, improve patient monitoring and lower the risk of avoidable complications. Demand is also being driven by the expansion of outpatient care, remote monitoring and therapies designed for patients who may not be suitable for traditional surgical procedures. Because these devices operate so closely to patient risk and long-term outcomes, product reliability, regulatory discipline and strong clinical evidence remain critically important across the industry.
Q3
How Should Healthcare Decision-Makers Evaluate Cardiovascular Device Companies?
Evaluation should begin with the clinical problem the device addresses. A strong company should show credible evidence, clear indications for use, consistent manufacturing quality and practical fit within existing cardiology workflows. Decision-makers should also examine training requirements, service response, data handling, reimbursement alignment and supply continuity. Top Cardiovascular Device Companies are often judged by how well their products perform beyond controlled settings: in busy cath labs, electrophysiology suites, ambulatory monitoring programs and post-procedure follow-up.
Q4
What Value Do Cardiovascular Devices Create for Hospitals and Patients?
Cardiovascular devices can improve care by supporting faster diagnosis, more precise intervention and better long-term disease management. For hospitals, value may appear through fewer repeat procedures, better physician confidence, reduced monitoring gaps and stronger documentation. For patients, the impact may be felt in shorter recovery times, fewer clinic visits, earlier detection of rhythm changes or improved symptom control. Top Cardiovascular Device Companies earn attention when their technologies connect measurable clinical benefit with practical use by physicians, nurses and technicians.
Q5
How Are Technology and Expertise Changing the Cardiovascular Device Market?
The realm is extending beyond a standalone piece of hardware. Cardiac monitoring equipment is becoming increasingly reliant on software, secure data transmission, and physician dashboards/logic which needs to ignore noise but recognize a "meaningful" shift. Implantable and minimally invasive hardware needs to be robust and underpinned with robust engineering, material science and procedural understanding. While AI could help to manage signal processing and triaging, it must be carefully validated. Skillset remains important; something that looks technically advanced on paper will flop if it hinders procedures or is difficult for staff to learn.
Q6
What Should Healthcare Organizations Prioritize When Comparing Providers?
Healthcare organizations should prioritize clinical evidence, safety profile, ease of adoption, regulatory maturity, service quality and total cost of use. Procurement teams should also consider whether the company can support training, device availability, software updates and post-market surveillance. Top Cardiovascular Device Companies should be assessed through the lens of real cardiac care: procedure time, monitoring accuracy, physician learning curve, patient follow-up and integration with hospital systems. The strongest choice is rarely based on a single feature.